UBS launched its "House of Craft" initiative in New York, celebrating craftsmanship in the watchmaking industry amid its integration of Credit Suisse. The three-day event featured discussions with industry leaders and celebrities, aiming to enhance brand awareness and connect with potential clients. The campaign, part of a broader strategy to define UBS's identity post-merger, emphasizes the bank's legacy and commitment to excellence.
18:36 18.10.2024
MERCK KGAA's Capital Markets Day sparked a 7.6% market rise, despite dampened pharmaceutical expectations following setbacks in drug development. The Electronics division, particularly Semiconductor Materials, is projected to grow sales by 5-9% annually, while pharmaceuticals anticipate slight growth through licensing. Analysts remain optimistic, with target prices from DEUTSCHE BANK at €180 and GOLDMAN SACHS at €205, reflecting a calming effect from the event.
Ramsay Santé reported a 6.5% increase in sales for the 2024 financial year, reaching 5 billion euros, driven by growth across all regions. However, the company faced a net loss of 53.9 million euros, down from a profit of 49.4 million euros last year, due to lower subsidies, rising costs, and staff shortages, leading to a decline in Ebitda margin from 13.2% to 12.2%. CEO Pascal Roché highlighted ongoing underfunding in the healthcare sector despite efforts to secure recognition for private hospitals' contributions.
Datadog's shares rose 1.4% to $128 after UBS upgraded the cloud security firm to 'buy' from 'neutral', raising the price target by $25 to $150, indicating a potential 19% upside. UBS noted signs of spending improvement in the cloud infrastructure sector, which could support Datadog's growth rate in the coming quarters. Currently, 11 brokerages recommend a "strong buy," while 27 suggest "buy," with a median price target of $150.
18:16 18.10.2024
Karen Lynch has stepped down as President and CEO of CVS Health, replaced by David Joyner, effective October 17, following disappointing preliminary financial guidance for Q3. The company faces ongoing challenges with elevated medical costs, leading to significant restructuring charges and a 13% drop in shares. Joyner, with extensive healthcare experience, aims to lead CVS through these difficulties while acknowledging Lynch's contributions during her tenure.
Amphastar Pharmaceuticals (AMPH) is poised for another earnings beat, having surpassed estimates in its last two quarterly reports by an average of 27.79%. With a positive Earnings ESP of +10.35% and a Zacks Rank #3, analysts are optimistic about the company's upcoming performance. Historically, stocks with this combination have a nearly 70% chance of exceeding consensus estimates.
TME Pharma N.V. reported significant advancements in its clinical and regulatory efforts for NOX-A12, a treatment for glioblastoma, achieving a median overall survival of 19.9 months in a recent trial. The FDA granted Fast Track designation and cleared an IND application for a Phase 2 study, paving the way for accelerated development. The company also raised €5 million in funding, enhancing its financial position as it prepares for further clinical trials.
Turin's labor market in 2024 reflects a blend of tradition and innovation, with an average salary of €32,000, lower than Milan and Rome. The technology sector thrives with salaries between €35,000 and €50,000, while the service sector lags at €22,000 to €26,000. Despite a lower cost of living than Milan, rising rents challenge purchasing power, necessitating a focus on education and training to address wage disparities.
Vietnam’s VPBank has partnered with CleverTap to enhance customer engagement through hyper-personalised banking experiences. By leveraging CleverTap’s AI/ML capabilities, VPBank aims to gain insights into customer behavior, enabling tailored interactions and contextual offers to boost customer lifetime value. This collaboration positions VPBank as a leader in Vietnam’s evolving banking sector, focusing on innovation and customer-centricity.
17:43 18.10.2024
MedAxiom has partnered with Shockwave Medical to promote the benefits of intravascular lithotripsy (IVL) technology, which effectively breaks up severely calcified plaques in arteries. Acquired by Johnson & Johnson MedTech, Shockwave's IVL has received FDA approval for treating both peripheral arterial disease and coronary artery disease, showing significant improvements in PCI outcomes. MedAxiom, a consulting firm focused on cardiology, aims to navigate the complexities of the healthcare environment for heart teams.

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings